Erratum to: Gene expression profiling of breast tumor cell lines to predict for therapeutic response to microtubule-stabilizing agents

Erratum to: Breast Cancer Res Treat DOI 10.1007/s10549-011-1687-8

Author would like to amend the following corrections in the below Tables 3 and 4 which has been published unnoticed in the original version. Where, the article included an unfortunate inversion between “Neg” and “Pos” rows for “ER”, “PR”, “Ki67” and “P53” in Tables 3 and 4. In Table 4, there was also an error in the percentages of grade 1 and 2 tumors with predicted taxane-sensitive and ixabepilone-resistant phenotype. The correct values are given in the tables presented below.

Table 3 Clinical, pathological and molecular characteristics of 266 early breast cancer patients, according to their predicted sensitivity to taxanes and ixabepilone

Table 4 Clinical, pathological and molecular characteristics of 46 early breast cancer patients, predicted to have differential sensitivity to taxanes and ixabepilone